#semaglutide

19 articles tagged #semaglutide.

Ready to compare providers? Take the 2-minute match quiz or see the cheapest GLP-1 options.

#2026 4#503a 1#503b 2#FDA 1#alternatives 1#ban 1#before-and-after 1#beginners 2#brand-name 3#bridge-program 1#cagrilintide 1#cagrisema 1#comparison 2#compounded 8#compounded-semaglutide 1#compounded-tirzepatide 1#compounding-ban 1#copay 1#cost 13#coupon 1#coverage 1#diabetes 1#diet 1#dosage 1#eli-lilly 3#enforcement 1#enrollment 1#fact-check 1#fda 3#fda-approval 1#flat-rate 1#foundayo 7#framework 1#glp-1-patches 1#glucose-monitors 1#guide 1#hhs 1#hims 1#how-to-get 1#injectable 7#injection 1#insulin-resistance 1#insurance 11#ivy-rx 1#ivyrx 1#legality 1#liraglutide 1#medicaid 1#medicare 5#mounjaro 6#news 2#novo-nordisk 2#oral-glp1 6#oral-semaglutide 1#orforglipron 4#ozempic 7#pcos 1#pill 1#pipeline 1#policy 1#prior-authorization 2#regulation 2#results 1#rfk 1#ro 1#safety 3#savings-card 1#schedule 1#semaglutide 19#shortage 1#side-effects 9#supplements 1#surmount 2#surmount-5 1#telehealth-enforcement 1#telehealth-review 1#timeline 1#tirzepatide 18#type-2-diabetes 1#warning-letters 1#wegovy 16#wegovy-hd 1#wegovy-pill 3#weight-loss 26#without-insurance 1#zepbound 17
Editorial still-life illustrating two parallel paths, a calm side-by-side comparison
AnalysisComparisonsJune 24, 2026• 11 min read

Mounjaro vs Ozempic (2026): The Honest Head-to-Head Your Doctor Won't Have Time For

Mounjaro (tirzepatide) and Ozempic (semaglutide) are both FDA-approved only for type 2 diabetes, neither is approved for weight loss (that's their sister brands, Zepbound and Wegovy). In the first head-to-head trial, SURMOUNT-5, tirzepatide beat semaglutide for weight loss (−20.2% vs −13.7% over 72 weeks), and in SURPASS-2 tirzepatide cut A1C more. But Ozempic's semaglutide has the SELECT cardiovascular outcome data Mounjaro doesn't. Here's the data-driven breakdown, plus the cheaper cash-pay paths if your insurance says no.

Editorial still-life evoking metabolic balance and women's health, warm natural light
GuideCost & InsuranceJune 24, 2026• 11 min read

GLP-1 for PCOS (2026): Ozempic, Wegovy & Cheaper Compounded Paths

GLP-1 medications like Ozempic and Wegovy can help PCOS because the syndrome is driven by insulin resistance, and these drugs improve insulin sensitivity, drive weight loss, and in trials restored menstrual regularity and raised natural-pregnancy rates. But here is the catch almost no one explains: PCOS by itself is NOT an FDA-approved reason to prescribe any GLP-1, so insurance and brand savings cards hinge on your BMI and comorbidities, not your PCOS diagnosis. This guide covers the trial signal, why insurance denies PCOS-only requests, the BMI rules behind savings cards, and the cheaper cash-pay paths if you do not qualify.

Editorial lifestyle photograph illustrating a morning wellness routine with a glass of water on a clean kitchen counter
GuideComparisonsJune 22, 2026• 10 min read

Oral GLP-1 Pills for Weight Loss (2026): Foundayo, Oral Semaglutide (Wegovy) & All Options

As of 2026, two FDA-approved oral GLP-1 pills exist for weight loss: Foundayo (orforglipron, 12.4% weight loss, $149/mo self-pay via LillyDirect, no fasting needed, approved April 1) and the Wegovy pill (semaglutide 25mg, 16.6% weight loss, $1,349/mo list price, requires 30-min fast before dosing, approved December 2025). Rybelsus is oral semaglutide but approved for type 2 diabetes only, not weight loss.

Editorial photograph illustrating the FDA compounded semaglutide enforcement crackdown
NewsCost & InsuranceJune 19, 2026• 13 min read

Compounded Semaglutide Ban (2026): FDA Crackdown Explained + 4 Legal Switch Options

Updated June 29, 2026: FDA issued 30 warning letters to telehealth companies June 15 for illegally marketing compounded GLP-1s. 503B permanent exclusion comment period extended to July 30, 2026 (from June 29 via FR 2026-12937). FDA proposed April 30 to permanently remove semaglutide, tirzepatide, and liraglutide from the 503B Bulks List. 503A enforcement began April 22, 2025. 503B enforcement May 22, 2025. 3-4 million patients affected. Legal alternatives: compounded tirzepatide ($149-299/mo, medical-necessity only), Wegovy $349/mo via NovoCare, or Foundayo from $149/mo self-pay.

Editorial still-life illustrating CagriSema, an investigational injectable weight loss drug from Novo Nordisk
AnalysisNews & PipelineJune 16, 2026• 9 min read

CagriSema 2026: Weight Loss Results, FDA Timeline & Why You Can't Buy It Yet

CagriSema (cagrilintide + semaglutide) lost 22.7% average body weight in adults with obesity (REDEFINE 1) and 13.7% in adults with type 2 diabetes (REDEFINE 2) over 68 weeks. Novo Nordisk filed its US application on December 18, 2025; an FDA decision is expected later in 2026 with no public PDUFA date. It is not FDA-approved and not legally available as of June 2026, here is the honest data, how it stacks up against drugs you can get today, and why every site selling 'CagriSema' right now is a red flag.

Editorial lifestyle photograph of official documents on an oak desk illustrating a regulatory proposal
NewsNews & PipelineMay 8, 2026• 7 min read

FDA Proposes Permanent 503B Compounding Ban for Semaglutide, Tirzepatide & Liraglutide

Verified May 8, 2026, Updated June 29, 2026: On April 30, FDA proposed permanently removing semaglutide, tirzepatide, and liraglutide from the 503B outsourcing bulk list, forever, not just during shortage enforcement. Public comment period extended to July 30, 2026 (from June 29 via Federal Register 2026-12937, published June 26, 2026). If finalized, no 503B pharmacy could bulk-compound these GLP-1 drugs in the future, even if a new shortage is declared. 503A patient-specific compounding under medical-necessity remains unaffected.

Editorial lifestyle photograph illustrating a beginner guide to GLP-1 weight loss medications
GuideGuidesApril 13, 2026• 12 min read

GLP-1 Receptor Agonists for Weight Loss 2026: FDA-Approved Options, Cost & Prescription Guide

FDA-approved GLP-1 receptor agonists for weight loss, 2026 guide. Eligibility: BMI 30+ (or 27+ with comorbidity). Semaglutide produces 14.9% weight loss (STEP-1), tirzepatide 20.9% (SURMOUNT-1). Cost: $25-$349/mo via telehealth. Complete 5-step prescription process with verified provider pricing. Options: Foundayo (orforglipron), oral Wegovy, Zepbound, and injectable semaglutide.

Featured Partners

Four affiliate partners we feature, we may earn a commission.

Yucca Health

7.7/10
$146/mo·Compounded
Visit Yucca HealthReview

Gala

7.2/10
$149/mo·Brand & Compounded
Visit GalaReview

TrimRx

7.8/10
$149/mo·Compounded
Visit TrimRxReview

SkinnyRx

7.3/10
$199/mo·Compounded
Visit SkinnyRxReview

Affiliate links, we earn a commission at no extra cost to you. These are featured partners, prioritized by our affiliate economics, not an editorial "best" ranking. The objective ranking (by methodology score) and full methodology are at glp1picks.com/best.